Rigel Pharmaceuticals(RIGL)
SOUTH SAN FRANCISCO, CAPharmaceutical
Focus: Rigel is a public-stage specialty pharma company headquartered in South San Francisco focused on small-molecule therapeutics in neurology and hematology/oncology. The company generates ~$117M in annual revenue with significant concentration in its lead product TAVALISSE.
Profile data last refreshed 23h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Rigel Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Rigel Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Rigel Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
6 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$117M
Key Products
$40M Part DStable
Peak5.8yr
Company's flagship and 85% revenue driver; small-molecule Syk inhibitor with extended patent protection until 2032 provides revenue backbone but concentrates portfolio risk.
Help build intelligence for Rigel Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.